DHX9 and Ewing sarcoma: Finally, the inhibition of EWS-FLI1 binding to RNA helicase A (RHA), which is important for its oncogenic function, was shown to have therapeutic relevance [138,139], while functional, genomic and super-enhancer screenings identified a peculiar sensitivity of Ewing sarcomas to the Cyclin D1/CDK4 pathway [140], and to Poly-ADP-ribose polymerase (PARP) inhibitors [141,142].